dr. wakelee discusses adjuvant therapy predictive markers
Published 12 years ago • 250 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:13
dr. wakelee discusses the future of lung cancer adjuvant therapy
-
1:52
dr. wakelee discusses adjuvant therapy in elderly nsclc patients
-
1:26
dr. wakelee on explaining adjuvant therapy benefits to patients
-
17:16
gracecast-028_lung-cancer_heather wakelee on nsclc adjuvant therapy
-
1:23
dr. wakelee discusses current state of treatment in nsclc
-
1:59
gracecastuc-026_lung_dr. wakelee on using molecular marker info for mgmt. of earlier stage nsclc
-
1:33
dr. wakelee on continued maintenance in lung cancer
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:19
dr. wakelee on combining targeted agents for the treatment of lung cancer
-
1:55
dr. heather wakelee discusses nintedanib plus chemotherapy in nsclc
-
0:46
dr. capitanio discusses adjuvant therapy for high-risk kidney cancer
-
0:55
dr. heather wakelee discusses the avaperl trial
-
9:24
impower010 supports adjuvant atezolizumab in early-stage nsclc | heather wakelee
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
1:27
dr. heather wakelee on "which molecular marker tests do you seek?"
-
1:35
dr. wakelee on unmet needs for immunotherapy in nsclc
-
1:27
dr. wakelee discusses egfr tkis in lung cancer
-
1:03
dr. wakelee discusses dacomitinib in egfr nsclc
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc